https://clinicaltrials.gov/ct2/show/NCT02275208
"A Prospective, Multi-center, Single-arm Study of the Stomach, Intestinal and Pylorus Sparing (SIPS) Procedure"
Primary Outcome Measures:
Secondary Outcome Measures:
Estimated Enrollment:120
Study Start Date:November 2014
Estimated Study Completion Date:November 2016
Estimated Primary Completion Date:November 2016 (Final data collection date for primary outcome measure)
Detailed Description:
SIPS is a single-anastomosis duodeno-intestinal switch procedure. Preliminary data from Sanchez-Pernaute et al. (Surg Obes Relat Dis 2013;9:731) indicates that this procedure is safe, quick to perform, and offers good results for treatment of both morbid obesity and its metabolic comorbidities. CovidienTM plans to further investigate this procedure and has proposed a prospective clinical study to obtain data on subject outcomes through 12 months following the SIPS procedure.
Criteria
Inclusion Criteria:
But hey, a clinical trial is a GOOD thing – real data, eventually. I’ll be interested in seeing the dietary recommendations.
Why do you suppose it is only a 12 month study?? That is WORTHLESS to prove anything – is this simply a PLOY to quickly get past the insurance companies’ refusal to cover it? Also, why is Medtronic/Covidien paying for the study? To sell more staples??
But most importantly for those who feel they were deceived by any of those surgeons, I think this clinical trial may be an admission at LEAST of the participating surgeons that the SIPS is experimental, and if this was not disclosed to you, especially after the start date for the clinical trial of November 2014, there may have been a serious violation of your rights. Your lawyer might want to know about this trial.
"A Prospective, Multi-center, Single-arm Study of the Stomach, Intestinal and Pylorus Sparing (SIPS) Procedure"
Primary Outcome Measures:
- The primary endpoint is excess weight loss (EWL) at 12 months. [ Time Frame: 12 months ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- SIPS-related adverse events at all timepoints [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]
- Resolution of comorbidities at 1, 6, and 12 months [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]
- Quality of life (QOL) (SF-36 and gastroesophageal reflux disease - health related quality of life [GERD-HRQL]) at 6 and 12 months [ Time Frame: 12 months ] [ Designated as safety issue: No ]
Estimated Enrollment:120
Study Start Date:November 2014
Estimated Study Completion Date:November 2016
Estimated Primary Completion Date:November 2016 (Final data collection date for primary outcome measure)
Detailed Description:
SIPS is a single-anastomosis duodeno-intestinal switch procedure. Preliminary data from Sanchez-Pernaute et al. (Surg Obes Relat Dis 2013;9:731) indicates that this procedure is safe, quick to perform, and offers good results for treatment of both morbid obesity and its metabolic comorbidities. CovidienTM plans to further investigate this procedure and has proposed a prospective clinical study to obtain data on subject outcomes through 12 months following the SIPS procedure.
Criteria
Inclusion Criteria:
- The subject must be 18-65 years of age
- The subject must be willing and able to participate in the study procedures and to understand and sign the informed consent
- The subject is under consideration for surgery for obesity or metabolic disease and elects to undergo a primary SIPS procedure
- The subject has a BMI of 35-40 kg/m2 with at least 1 obesity-related comorbidity or a BMI of 40-60 kg/m2
- Any female subject who is pregnant, or is actively breast-feeding
- Any subject who is considered to be part of a vulnerable population (e.g. prisoners or those with psychological concerns or those without sufficient mental capacity)
- The procedure is an emergency procedure
- The procedure is a revision/reoperation for the same indication
- The subject is unable or unwilling to comply with the study requirements or follow-up schedule
- The subject has conditions which, in the opinion of the investigator, will not be appropriate for the study (e.g. severe cardiovascular disease, history of gastrointestinal (GI) malignancy, history of upper GI surgery, open cholecystectomy, history of intestinal surgery, immunosuppression, or non-ambulatory)
- The subject has an estimated life expectancy of less than 6 months
- The subject has participated in an investigational drug or device research study within 30 days of enrollment
· Colorado: Metz
· NY, both Mt. Kisco and NYC: Roslin
· North Carolina:
· NY, both Mt. Kisco and NYC: Roslin
· North Carolina:
o Cary is Enoch
o Durham is Sudan (?)
· Utah: Cottamo Durham is Sudan (?)
But hey, a clinical trial is a GOOD thing – real data, eventually. I’ll be interested in seeing the dietary recommendations.
Why do you suppose it is only a 12 month study?? That is WORTHLESS to prove anything – is this simply a PLOY to quickly get past the insurance companies’ refusal to cover it? Also, why is Medtronic/Covidien paying for the study? To sell more staples??
But most importantly for those who feel they were deceived by any of those surgeons, I think this clinical trial may be an admission at LEAST of the participating surgeons that the SIPS is experimental, and if this was not disclosed to you, especially after the start date for the clinical trial of November 2014, there may have been a serious violation of your rights. Your lawyer might want to know about this trial.
Last edited: